Current Clinical Trials

ADULT CANCER RESEARCH

• Breast
• Alliance A012103: OptimICE-PCR: Deescalation of Therapy in Early Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
• Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests
• NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
• SWOG S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
• Latimer breast cancer fresh tissue and blood study (Biomarker)
• Retrospective analyses of genetic testing performed in patients with breast, ovarian and endometrial cancer
• Endometrial
• GOG-3083: A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter Trial Of Selinexor In Maintenance Therapy after systemic Therapy For Patients With P53 Wild-type, Advanced Or Recurrent Endometrial Carcinoma
• NRG-GY-026: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Open to accrual: Upfront treatment for stage I-IV uterine serous carcinoma or carcinosarcoma
• Ovarian
• GOG-3078: Platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancers using an antibody drug conjugate
• NRG-GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA 1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
• Head and Neck
• The efficacy of topical fibrin sealant in the reduction of postoperative pain after head and neck surgery
• Biospecimen
• Utility of molecular diagnostics from cervicovaginal sampling in endometrial cancer
• SERATRIALS-18004: A Multi-Center Study for the Collection of Biospecimens for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research
• MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
• AOA-PR-0001:  Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
• Other
• EAY191: Molecular Analysis for Combination Therapy Choice (Combo Match)
• GOG3088:  A Randomized Phase II Study of Letrozole Vs. Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma
• GOG-3112:  A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Vs. Bevacizumab Monotherapy as First-Line Therapy in HER2-Expressing Ovarian Cancer (DESTINY)
• Moonshot:  National Cancer Institute / Cancer Moonshot Biobank Research Protocol
• GOG3116:  A Propsective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with TIVDAK in Recurrent or Metastatic Cervical Cancer

CARDIOVASCULAR RESEARCH

• Dal-GenE-2:  A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effecs of Dalcetrapib on Cardiovascular (CV) Risk in Genetically Defined Population with a Recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) Trial
• INTEGRA-D: Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects with Heart Failure and Reduced Ejection Fracture
• Librexa Afib Study: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

PEDIATRIC CANCER

• Leukemia
• AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
• AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-risk B-ALL; Risk-Adapted Post-induction Therapy for High-risk B-ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy 

• Other
• ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
• APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
• AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
• APEC14B1: A Children’s Oncology Protocol for Project: Every Child: A Registry, Eligibility Screening, Biology, and Outcome Study
• AREN2231:  Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
• ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
• AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and A Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
• ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, nad Cyclophosphamide (VINO-AC) vs. Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
• AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
• ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
• APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
• ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
• AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
• DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)